Registry on local treatment methods for Myxoid Liposarcoma
International Prospective Registry on Local Treatment Approaches in Myxoid Liposarcomas
This study is testing different local treatment options for people with Myxoid Liposarcoma to see which methods work best.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The Netherlands Cancer Institute Academic / other |
| Locations | 1 site (Amsterdam) |
| Trial ID | NCT04699292 on ClinicalTrials.gov |
What this trial studies
This study aims to prospectively evaluate various local treatment approaches for patients with Myxoid Liposarcoma (MLS). It will compare outcomes from different treatment modalities, including surgery and various radiation therapy doses, to confirm previous findings from the DOREMY trial. The study will collect and analyze data from multiple institutions to enhance understanding of effective treatment strategies for MLS.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 with biopsy-proven Myxoid Liposarcoma and an ECOG performance status of 0-2.
Not a fit: Patients who have received prior radiotherapy to the target area or are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment protocols for patients with Myxoid Liposarcoma.
How similar studies have performed: Other studies have shown promising results with similar treatment approaches, indicating potential for success in this registry.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years * Biopsy proven MLS, including the reciprocal chromosomal translocation t(12;16)(q13;p11) * ECOG PS 0-2 * Written informed consent to share coded information in this international Registry Exclusion Criteria: * Prior radiotherapy to the target area * Pregnancy
Where this trial is running
Amsterdam
- The Netherlands Cancer Institute — Amsterdam, Netherlands (Recruiting)
Study contacts
- Principal investigator: Rick Haas, MD/PhD — The Netherlands Cancer Institute
- Study coordinator: Rick Haas, MD/PhD
- Email: r.haas@nki.nl
- Phone: +31 20 512 9111
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.